



Martin Dow

Pharmaceuticals for a Changing World

Martin Dow Pharmaceuticals Meymac





Vision

Martin Dow is a Corporate Force that is positioned to create long term value for the society and its Stakeholders



Mission


- To become the most admired company
- To be the fastest growing company



Values


- ✦ Respect & Dignity
- ✦ Transparency / Integrity
- ✦ Share success with Community & Employees
- ✦ Socially Responsible
- ✦ Talent / Teamwork

Martin Dow Group Corporate History snapshot




Martin Dow Pharmaceuticals

Meymac Plant



- Former Bristol-Myers Squibb plant
- Dedicated to oral solid dosage forms
- 13,000 m² on grounds of 9.6 ha
- Experienced Personnel
- Strong focus on being the adequate partner in niche projects

Site Overview



1	Production and QC Labs
2	Shipping area
3	Admin building
4	Maintenance
5	Receiving area
6	High height warehouse
7	Technical premises
8	Solvents
9	Guard house


As Contract Development & Manufacturing Organization, we focus on Dry Oral Solid dose forms (capsules, tablets & sachets).

Our capabilities and expertise enable us to offer dedicated services such as:

- Import, retest & release for EU imported drugs
- of oral solids (capsules, tablets & sachets)
- Development, Scale-Up and Manufacturing of semi-finished & finished products with primary and secondary packaging
- Analytical services (methods dev., transfer & validation; routine release and stab. testing)
- Microbio tests
- Warehousing

The current production operating process

1. APIs, Excipients, Semi Finished DP and Packaging items reception
2. Granulation, Compaction, Compression, Hard Caps & sachets Filling
3. Packaging (blisters, bottles) & Cartoning followed by Release and shipment



Organizational chart

MARTIN DOW
PHARMACEUTICALS MEYMAC

Group Director
Finance & IT
A. Aamir

Directeur Qualité
Pharmacien Responsable
E. Teilhet

Directeur de Site
A. Schwenck

Assistante Qualité
V. Chassaing

Sr Dir Legal HR &
Admin
A. Gallagher

Assistante de
Direction
E. Hardouin

Business Dèv.
H. Benevent

Chargée de Dev.
Produit
M. Bourgaut

Directeur Finances

AQ Produit
A. Bénêteau

AQ Compliance
C. Chan

CQ
B. Dallet

M/I Développement
E. Feintrenie

Production
A. Schwenck *acting*

Moyens Généraux
JR Arias

LogistiqueMagasin
P. Rousayrol

Compta/Finance
L. Lunard

Technicienne
S. Guiavarch

Techniciennes
A. Vinatier
C. Gourdièr
S. Puche

Opératrice
N. Ly

Validation
A. M'Dere

Techniciens
F. Vergne
C. Vigues

Opérateurs
P. Monange
S. ternat
F. Meunier
B. Brunhoghe
E. Mavier

Techs. Maintenance
F. Benard
L. Bouyge
R. Pinlet
Th. Chevallier

Agent Maint.
Ph. Bezouh

Magasiniers
S. Rigal
M. Joutoux

Meymac's Customers portefollio

Following re-opening and grant of GMP certificate in March 2017, we have succeeded already to have:

- 4 customers (North Africa, France, Pakistan, Swiss)
- Plus several offers under discussion (mainly Europe)

Strong niche commercial focus

- **High containment area (operational by early 2019)**
- **Humidity controlled processes (35% RH)**
- **Customised projects (dedicated area & services)**
- **Flexible organization (small batch, controlled drugs...)**

Investment effort supported by corporate & regional funds

- **1 mid-size Coater in production**
- **Datamatrix module / Serialization**
- **1 hard capsule equipment**
- **Low Humidity modules**
- **HAPI Area**

Capacities

Section / Equipment	Units	(1 shift)
---------------------	-------	-----------

Manufacturing

Granulation (wet and dry)	000's Kgs	180
Tablet Compression	Mill Tab	350
<i>Coating</i>	000's Kgs	50
Capsule Filling	Mill Cap	250

Packaging

Blister Machine	Mill Blist	8
Sachet Filling Machine	Mill Sach	90
Bottle filling machine (caps, tabs)	Mill Bott	2
Semi manual, customized on demand	Mill Blist	2

Mixing capacities

Densité produit : 0,5
Taux de remplissage : 30%

Nombre de containers	Containers	Capacité
1	150	23 kg
12	600	90 kg
16	1000	150 kg
47	2000	300 kg

QC Laboratory

- **Physico-chemistry:**
IR, HPLC, Gas-Chromato, Dissolution, Aggregation, Conductivity,
Potentiometric dosing, Spectro IR / UV, Karl Fischer
- **Microbiology**
- **Stability**
- **EU import retest and release**

Benefits to work with MDP

- **Restarting site → flexible offering**
- **Expertise and Dedication**
- **Ongoing plan of recruitment & high investment**
- **Different collaboration models:** co-development, co-investment, participation in sales profits, ...

Conclusion

Martin Dow Pharmaceuticals has the strong willingness to build **close partnerships** to succeed in launching / transferring in the **shortest timelines** and on **cost effective model** from an **European site**.

Martin Dow Pharmaceuticals commits to establish **long term relationship** based on **customer needs dedication**.